237 related articles for article (PubMed ID: 10930536)
1. An investigation into the formation of N- [2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA) and 6-[2-(dimethylamino)ethylamino]- 3-hydroxy-7H-indeno[2, 1-C]quinolin-7-one dihydrochloride (TAS-103) stabilised DNA topoisomerase I and II cleavable complexes in human leukaemia cells.
Padget K; Stewart A; Charlton P; Tilby MJ; Austin CA
Biochem Pharmacol; 2000 Sep; 60(6):817-21. PubMed ID: 10930536
[TBL] [Abstract][Full Text] [Related]
2. Establishment and characterization of 6-[[2-(Dimethylamino)ethyl]amino]-3-hydroxy-7H-indeno[2,1-c]quinolin-7-one dihydrochloride (TAS-103)-resistant cell lines.
Aoyagi Y; Kobunai T; Utsugi T; Wierzba K; Yamada Y
Jpn J Cancer Res; 2000 May; 91(5):543-50. PubMed ID: 10835500
[TBL] [Abstract][Full Text] [Related]
3. Antitumor activity of a novel quinoline derivative, TAS-103, with inhibitory effects on topoisomerases I and II.
Utsugi T; Aoyagi K; Asao T; Okazaki S; Aoyagi Y; Sano M; Wierzba K; Yamada Y
Jpn J Cancer Res; 1997 Oct; 88(10):992-1002. PubMed ID: 9414662
[TBL] [Abstract][Full Text] [Related]
4. Topoisomerase I/II selectivity among derivatives of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA).
Bridewell DJ; Finlay GJ; Baguley BC
Anticancer Drug Des; 2001 Dec; 16(6):317-24. PubMed ID: 12375884
[TBL] [Abstract][Full Text] [Related]
5. Mechanism of cytotoxicity of N-[2-(dimethylamino)ethyl] acridine-4-carboxamide and of its 7-chloro derivative: the roles of topoisomerases I and II.
Bridewell DJ; Finlay GJ; Baguley BC
Cancer Chemother Pharmacol; 1999; 43(4):302-8. PubMed ID: 10071981
[TBL] [Abstract][Full Text] [Related]
6. In vitro antitumor activity of TAS-103 against freshly-isolated human colorectal cancer.
Tsunoda T; Tanimura H; Yamaue H; Ishimoto K; Kobunai T; Yamada Y
Anticancer Res; 2001; 21(6A):3897-902. PubMed ID: 11911266
[TBL] [Abstract][Full Text] [Related]
7. Camptothecin-stabilised topoisomerase I-DNA complexes in leukaemia cells visualised and quantified in situ by the TARDIS assay (trapped in agarose DNA immunostaining).
Padget K; Carr R; Pearson AD; Tilby MJ; Austin CA
Biochem Pharmacol; 2000 Mar; 59(6):629-38. PubMed ID: 10677579
[TBL] [Abstract][Full Text] [Related]
8. Formation and longevity of idarubicin-induced DNA topoisomerase II cleavable complexes in K562 human leukaemia cells.
Willmore E; Errington F; Tilby MJ; Austin CA
Biochem Pharmacol; 2002 May; 63(10):1807-15. PubMed ID: 12034365
[TBL] [Abstract][Full Text] [Related]
9. A dual topoisomerase inhibitor, TAS-103, induces apoptosis in human cancer cells.
Ohyama T; Li Y; Utsugi T; Irie S; Yamada Y; Sato T
Jpn J Cancer Res; 1999 Jun; 90(6):691-8. PubMed ID: 10429663
[TBL] [Abstract][Full Text] [Related]
10. From amsacrine to DACA (N-[2-(dimethylamino)ethyl]acridine-4-carboxamide): selectivity for topoisomerases I and II among acridine derivatives.
Finlay GJ; Riou JF; Baguley BC
Eur J Cancer; 1996 Apr; 32A(4):708-14. PubMed ID: 8695277
[TBL] [Abstract][Full Text] [Related]
11. Murine transgenic cells lacking DNA topoisomerase IIbeta are resistant to acridines and mitoxantrone: analysis of cytotoxicity and cleavable complex formation.
Errington F; Willmore E; Tilby MJ; Li L; Li G; Li W; Baguley BC; Austin CA
Mol Pharmacol; 1999 Dec; 56(6):1309-16. PubMed ID: 10570059
[TBL] [Abstract][Full Text] [Related]
12. Carbamate analogues of amsacrine active against non-cycling cells: relative activity against topoisomerases IIalpha and beta.
Turnbull RM; Meczes EL; Perenna Rogers M; Lock RB; Sullivan DM; Finlay GJ; Baguley BC; Austin CA
Cancer Chemother Pharmacol; 1999; 44(4):275-82. PubMed ID: 10447574
[TBL] [Abstract][Full Text] [Related]
13. Differences in the longevity of topo IIalpha and topo IIbeta drug-stabilized cleavable complexes and the relationship to drug sensitivity.
Errington F; Willmore E; Leontiou C; Tilby MJ; Austin CA
Cancer Chemother Pharmacol; 2004 Feb; 53(2):155-62. PubMed ID: 14504921
[TBL] [Abstract][Full Text] [Related]
14. Cytotoxic and DNA-damaging properties of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA) and its analogues.
Pastwa E; Ciesielska E; Piestrzeniewicz MK; Denny WA; Gniazdowski M; Szmigiero L
Biochem Pharmacol; 1998 Aug; 56(3):351-9. PubMed ID: 9744573
[TBL] [Abstract][Full Text] [Related]
15. Etoposide targets topoisomerase IIalpha and IIbeta in leukemic cells: isoform-specific cleavable complexes visualized and quantified in situ by a novel immunofluorescence technique.
Willmore E; Frank AJ; Padget K; Tilby MJ; Austin CA
Mol Pharmacol; 1998 Jul; 54(1):78-85. PubMed ID: 9658192
[TBL] [Abstract][Full Text] [Related]
16. DNA topoisomerases as targets for the anticancer drug TAS-103: primary cellular target and DNA cleavage enhancement.
Byl JA; Fortune JM; Burden DA; Nitiss JL; Utsugi T; Yamada Y; Osheroff N
Biochemistry; 1999 Nov; 38(47):15573-9. PubMed ID: 10569941
[TBL] [Abstract][Full Text] [Related]
17. Mechanism of action of the dual topoisomerase-I and -II inhibitor TAS-103 and activity against (multi)drug resistant cells.
Minderman H; Wrzosek C; Cao S; Utsugi T; Kobunai T; Yamada Y; Rustum YM
Cancer Chemother Pharmacol; 2000; 45(1):78-84. PubMed ID: 10647506
[TBL] [Abstract][Full Text] [Related]
18. DNA topoisomerases as targets for the anticancer drug TAS-103: DNA interactions and topoisomerase catalytic inhibition.
Fortune JM; Velea L; Graves DE; Utsugi T; Yamada Y; Osheroff N
Biochemistry; 1999 Nov; 38(47):15580-6. PubMed ID: 10569942
[TBL] [Abstract][Full Text] [Related]
19. Self-association and unique DNA binding properties of the anti-cancer agent TAS-103, a dual inhibitor of topoisomerases I and II.
Ishida K; Asao T
Biochim Biophys Acta; 2002 Jul; 1587(2-3):155-63. PubMed ID: 12084457
[TBL] [Abstract][Full Text] [Related]
20. 5,7-Disubstituted analogues of the mixed topoisomerase I/II poison N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA): DNA binding and patterns of cytotoxicity.
Spicer JA; Finlay GJ; Baguley BC; Velea L; Graves DE; Denny WA
Anticancer Drug Des; 1999 Feb; 14(1):37-45. PubMed ID: 10363026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
